If you have been reading about lyophilisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
===== MeSH D08.811.277.087 – amidohydrolases ===== MeSH D08.811.277.087.030 – N-acetylmuramoyl-L-alanine amidase MeSH D08.811.277.087.060 – allophanate hydrolase MeSH D08.811.277.087.100 – arylformamidase MeSH D08.811.277.087.116 – asparaginase MeSH D08.811.277.087.125 – aspartylglucosylaminase MeSH D08.811.277.087.180 – beta-lactamases MeSH D08.811.277.087.180.229 – cephalosporinase MeSH D08.811.277.087.180.697 – penicillinase MeSH D08.811.277.087.200 – biotinidase MeSH D08.811.277.087.280 – dihydroorotase MeSH D08.811.277.087.483 – glutaminase MeSH D08.811.277.087.520 – histone deacetylases MeSH D08.811.277.087.610 – nicotinamidase MeSH D08.811.277.087.690 – penicillin amidase MeSH D08.811.277.087.725 – peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase MeSH D08.811.277.087.760 – pyroglutamate hydrolase MeSH D08.811.277.087.831 – sirtuins MeSH D08.811.277.087.902 – urease
Nuclear magnetic resonance spectroscopy of proteins (usually abbreviated protein NMR) is a field of structural biology in which NMR spectroscopy is used to obtain information about the structure and dynamics of proteins, and also nucleic acids, and their complexes. The field was pioneered by Richard R. Ernst and Kurt Wüthrich at the ETH, and by Ad Bax, Marius Clore, Angela Gronenborn at the NIH, and Gerhard Wagner at Harvard University, among others. Structure determination by NMR spectroscopy usually consists of several phases, each using a separate set of highly specialized techniques. The sample is prepared, measurements are made, interpretive approaches are applied, and a structure is calculated and validated. NMR involves the quantum-mechanical properties of the central core ("nucleus") of the atom. These properties depend on the local molecular environment, and their measurement provides a map of how the atoms are linked chemically, how close they are in space, and how rapidly they move with respect to each other. These properties are fundamentally the same as those used in the more familiar magnetic resonance imaging (MRI), but the molecular applications use a somewhat different approach, appropriate to the change of scale from millimeters (of interest to radiologists) to nanometers (bonded atoms are typically a fraction of a nanometer apart), a factor of a million. This change of scale requires much higher sensitivity of detection and stability for long term measurement.
=== 2025: Australian Open final, 500th win === Alongside Team Germany, Zverev failed to defend the United Cup after withdrawing from the event due to injury. Entering the 2025 Australian Open as the second seed for the first time in his career, Zverev began his tournament with a dominant victory over 2019 semifinalist Lucas Pouille in the first round. He reached his second consecutive and third overall semifinal at the Australian Open defeating Pedro Martínez, Jacob Fearnley, Ugo Humbert, and Tommy Paul. Against the 24-time major champion, Zverev won the 81-minute first set against Djokovic before the latter's retirement due to injury, advancing to his third major final. In the final, Zverev lost to defending champion Jannik Sinner in straight sets. Following his defeat to Sinner, a visibly distraught Zverev delivered an emotional speech during the trophy ceremony, stating, "I want to thank my team... I'm just not good enough. It's as simple as that." In the post-match press conference, he reflected on his career trajectory and the pressure of being a perennial contender without a Major title, reportedly remarking that he "didn't want to be the best player in history without a Grand Slam", expressing his desperation to finally break the barrier after losing his third major final. Over the next two months, Zverev made quarterfinals at the South American events he played in, Buenos Aires and Rio de Janeiro, losing to Argentines Francisco Cerundolo and Francisco Comesana, respectively.
== Treatment == SAAM is treated by stopping the offending statin medication and taking immunosuppressive medications. In rare cases, affected people spontaneously improve after just stopping the implicated statin. However, most cases mandate the use of immunosuppressive medication. Corticosteroids are considered first-line treatment. Prednisone dosed at 1 milligram/kilogram of body weight daily is generally recommended. Corticosteroid therapy alone may be reasonable in cases of mild muscular weakness. More severe cases require the use of combined methotrexate, azathioprine, or mycophenolate with corticosteroids. Severe cases of SAAM may fail to respond to 8–12 weeks of combination therapy. Rituximab or intravenous immunoglobulin are recommended as add-on therapy in such cases. Intravenous immunoglobulin is an appropriate first-line therapy in select individuals. Suitable candidates for first-line intravenous immunoglobulin include people who have diabetes mellitus or who wish to avoid corticosteroid therapy.
Desmoplasia refers to growth of dense connective tissue or stroma. This growth is characterized by low cellularity with hyalinized or sclerotic stroma and disorganized blood vessel infiltration. This growth is called a desmoplastic response and occurs as result of injury or neoplasia. This response is coupled with malignancy in non-cutaneous neoplasias, and with benign or malignant tumors if associated with cutaneous pathologies. The heterogeneity of tumor cancer cells and stroma cells combined with the complexities of surrounding connective tissue suggest that understanding cancer by tumor cell genomic analysis is not sufficient; analyzing the cells together with the surrounding stromal tissue may provide more comprehensive and meaningful data.
Sources: en.wikipedia.org
== See also == Control of water pollution – Contamination of water bodies Clean Water Act – 1972 U.S. federal law regulating water pollution Peak water – Concept on the quality and availability of freshwater resources Pulsed-power water treatment – Using electro-magnetic fields on cooling water Solar water disinfection – Portable water purification powered by sunlight Raw water#Treatment – Untreated water found in a natural environment Water purification – Process of removing impurities from water Water quality – Assessment against standards for use Water softening – Removing positive ions from hard water Water supply – Provision of water by public utilities, commercial organisations or others
Mamadou Amadou Ly - Educationist, first African to be awarded the Yidan Prize, Time Magazine 100 Most influential people in the world (2026), Senegal. Amsatou Sow Sidibé- academic, lawyer and politician, Senegal Adji Bousso Dieng - assistant Professor of artificial intelligence, First African Faculty school of Engineering and applied science, Princeton University, Senegal. Ayuba Suleiman Diallo - Fulani Muslim prince and merchant, from Bundu, who was captured and sold to European slave traders after having just sold slaves himself. Ba Mamadou Mbare – former president of the Senate of Mauritania and former acting president of Mauritania, in office 15 April 2009 – 5 August 2009. The first black leader of Mauritania Baaba Maal – Singer and guitarist – Senegal Babacar Ba - former minister of finance, Foreign minister of Senegal. Cheikh Tidiane Gadio - Diplomat, former Minister of State, Minister of Foreign Affairs, Senegal Cherif Mohamed Aly Aidara - Shi'i religious leader, NGO founder, and international development leader Cheikh Hamidou Kane Mathiara - former Minister of the Armed Forces, Senegal Daouda Sow (politician)- Politician and legislator, former Minister and former president of the National Assembly, Senegal Doudou Ka - Former Minister of Economy, Planning and Cooperation, Senegal. Doudou Thiam - First Foreign Minister, Senegal. Djibo Leyti Kâ – Held multiple ministerial positions Including Foreign Affairs, National Education, Interior, Communication etc. in Senegal Fatoumata Ka - first female mayor in Senegal, mayor of the commune of Diourbel.
=== Applications in Infectious diseases === One way to detect these pathogens is detect part of their genome by metagenomics sequencing (Next Generation Sequencing-mNGS), which can be targeted or untargeted.
==== Males ==== CPA has been found to be effective in the treatment of acne in males, with marked improvement in symptoms observed at dosages of 25, 50, and 100 mg/day in different studies. It can also halt further progression of scalp hair loss in men. Increased head hair and decreased body hair has been observed with CPA in men with scalp hair loss. However, its side effects in men, such as demasculinization, gynecomastia, sexual dysfunction, bone density loss, and reversible infertility, make the use of CPA in males impractical in most cases. In addition, lower dosages of CPA, such as 25 mg/day, have been found to be better-tolerated in men. But such doses also show lower effectiveness in the treatment of acne in men.
Sources: en.wikipedia.org
Chemical information and Biochemical information. The chemical information includes more than 2,700 metabolite structures with detailed metabolite descriptions, extensive chemical classifications, synthesis information and observed/calculated chemical properties. It also contains nearly 5,000 NMR, GC-MS and LC-MS spectra from more than 600 different metabolites. The biochemical information includes >1,600 protein (and DNA) sequences and >3,100 biochemical reactions that are linked to these metabolite entries. The ECMDB supports many different types of online queries including text searches, chemical structure searches, sequence similarity searches and spectral similarity searches. This makes it particularly useful for metabolomic researchers who are studying E. coli as a model organism. Secondary electrospray ionization (SESI-MS) can discriminate between eleven E. Coli strains thanks to the volatile organic compound profiling.
=== Reflexes === The sense of proprioception is ubiquitous across mobile animals and is essential for the motor coordination of the body. Proprioceptive afferents form reflex loops with spinal alpha motor neurons to provide rapid feedback control of muscles. These mechanosensation circuits are important for flexibly maintaining posture and balance, especially during locomotion. For example, consider the stretch reflex, in which stretch of a muscle is detected by proprioceptors (e.g., muscle spindles in vertebrates, chordotonal neurons in invertebrates), which reflexly activate motoneurons to induce muscle contraction to oppose the stretch. During locomotion, inputs from Golgi tendon organs can reverse their reflex action on motoneurons to promote rather than oppose stretch-related orces.
== Ecology == Penicillium digitatum is found in the soil of areas cultivating citrus fruit, predominating in high temperature regions. In nature, it is often found alongside the fruits it infects, making species within the genus Citrus its main ecosystem. It is only within these species that P. digitatum can complete its life cycle as a necrotroph. However, P. digitatum has also been isolated from other food sources. These include hazelnuts, pistachio nuts, kola nuts, black olives, rice, maize, and meats. Low levels have also been noted in Southeast Asian peanuts, soybeans, and sorghum.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.